替罗非班
医学
血小板
阿昔单抗
丸(消化)
血管成形术
阿司匹林
氯吡格雷
麻醉
心脏病学
血小板聚集抑制剂
血小板糖蛋白GPIIb-iia复合物
内科学
血小板活化
药理学
心肌梗塞
传统PCI
作者
Franck Barbou,Corinne Frère,Thomas Hovasse,Thomas Cuisset,Lina Said,Jacques Quilici,Marie‐Christine Alessi,J.L. Bonnet
出处
期刊:PubMed
[National Institutes of Health]
日期:2006-10-01
卷期号:99 (10): 894-899
摘要
In the TARGET trial, the lower incidence of cardiac events at one month with abciximab compared with tirofiban was attributed to a lack of efficacy in the first hour because of suboptimal dosage. The object of this study was to confirm that high dose tirofibal is associated with over 90% platelet inhibition during the first hour and to analyse the effect of this new dosage on platelet activation. Thirty-three patients treated with clopidogrel and aspirin for an acute coronary syndrome without ST elevation were given before angioplasty a bolus of 25 microg/Kg of tirofiban injected in 3 minutes, followed by an infusion of 0.15 microg/kg/min. Blood samples were taken before the treatment (TO) and at the 45th minute (T1) to measure platelet aggregation induced by ADP, the expression of P-selection, the quantification of circulating monocyte-platelet aggregates and the phospholyration of VASP protein. The results showed that all patients had over 90% (100%) inhibition of platelet aggregation at T1. The expression of P-selection was significantly reduced (T0: 0.195 +/- 0.057 MFI; T1: 0.186 +/- 0.055 MFI, p = 0.03). There was no significant difference in the number of monocyte-platelet aggregates or in the phosphorylation of VASP. In conclusion, a bolus of 25 microg/Kg/3 min of tirofiban provides over 90% inhibition of platelet aggregation in the first hour. The initial platelet proactivator effect at this dosage was shown to have disappeared with an inhibition of platelet activation.
科研通智能强力驱动
Strongly Powered by AbleSci AI